logo-loader

Zynerba Pharmaceuticals anticipates data in late 2019 for its phase 3 cannabinoid drug

Published: 11:30 18 Oct 2018 EDT

Zynerba Pharmaceuticals (NASDAQ:ZYNE) CEO Armando Anido caught up with Proactive Investors' Christine Corrado at the BIO Investor Forum in San Francisco.

Zynerba is dedicated to developing next-generation transdermally-delivered cannabinoid therapeutics for rare and near-rare neuropsychiatric conditions in patients with high unmet medical needs.

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

50 minutes ago